This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad international audience of researchers and physicians to discuss the future of breast cancer research and treatment.
SABCS is designed to provide state-of-the-art information on a range of topics, including the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, to an international audience of academic and private physicians and researchers.
Based on that goal, many exciting abstracts and posters will be presented and discussed during the conference, many of which are turning their focus toward precision and targeted therapeutics that have changed the way we look at cancer treatment in the past several decades.
For an overview of oral and poster presentations about antibody-drug conjugates (ADCs) to be presented during the annual San Antonio Breast Cancer Symposium, December 5-9, 2017, Click here.
Much of today’s cancer research developments are being made in targeted therapy spaces, such as antibody-drug conjugates or ADCs.
At SABCS, the exciting oral presentations and posters dealing with ADCs, and other targeted therapeutics, are expected to provide invaluable information to physicians and researchers that are dealing with hard-to-treat patient populations that need more potent and better tolerable treatment options than what are currently available.
A summary of notable presentations and posters dealing with targeted therapeutics at SABCS can be found here.
This year, staring on Tuesday, December 5th, we will cover the annual San Antonio Breast cancer Conference.
Last Editorial Review: November 29, 2017
This article was first published on November 11, 2017 in ADC Review | Journal of Antibody-drug Conjugates
Featured Image: Breast cancer patient. Courtesy: © Fotolia. Used with permission.
Copyright © 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.